Development of the Calgary Symptoms of Stress Inventory (C-SOSI)

Development of the Calgary Symptoms of Stress Inventory (C-SOSI)
复制标题

DOI:
10.1007/bf03003000
复制
发表时间:
2007-01-01
影响因子:
2.7
通讯作者:
Thomas, Bejoy Cherian
Thomas, Bejoy Cherian
中科院分区:
心理学4区
文献类型:
--
作者:
Carlson, Linda E.;Thomas, Bejoy Cherian

文献摘要

被引文献

相似文献

目的:本研究的目的是开发一个修订版的压力症状量表(SOSI),卡尔加里SOSI(C-SOSI),这将是更短,更容易管理和评分,并具有良好的因素结构,可靠性和有效性用于肿瘤患者。方法:对344名登记参加压力管理项目的癌症患者进行SOSI。探索性因素分析(EFA)采用三个标准的基础上,共同性,因素负荷,和所需的分量表大小。将修订后的C-SOSI评分与生活质量、情绪障碍、睡眠和灵性测量评分相关,以开始聚合效度和区分效度的调查。结果如下:EFA产生了一个56项量表(从最初的94项减少),有8个分量表,每个分量表由6-9项组成,分别命名为:抑郁、愤怒、肌肉紧张、心血管唤醒、交感神经唤醒、神经/GI、认知障碍和上呼吸道症状。分量表的Cronbach α信度范围为0.80至0.95。收敛和判别效度的支持与其他措施的相关性,概念上的预测。结论:C-SOSI是一种可靠的工具,具有收敛效度,用于评估肿瘤人群的应激症状。建议开展进一步的验证工作,以支持在其他患者或社区群体中使用。
Objective: The objective of this study was to develop a revision of the Symptoms of Stress Inventory (SOSI), the Calgary SOSI (C-SOSI), which would be shorter, easier to administer and score, and have excellent factor structure, reliability, and validity for use with oncology patients. Methods: The SOSI was administered to 344 cancer patients registered for a stress-management program. Exploratory factor analysis (EFA) was applied using three criteria based on communality, factor loading, and desired subscale size. Scores on the revised C-SOSI were correlated with scores on measures of quality of life, mood disturbance, sleep, and spirituality to begin investigation of convergent and discriminant validity. Results: The EFA resulted in a 56-item scale (down from the original 94 items) with 8 subscales, each consisting of 6-9 items named: Depression, Anger, Muscle Tension, Cardiopulmonary Arousal, Sympathetic Arousal, Neurological/GI, Cognitive Disorganization, and Upper Respiratory Symptoms. Cronbach's alpha reliabilities for the subscales ranged from 0.80 to 0.95. Convergent and discriminant validity was supported by correlations with other measures as conceptually predicted. Conclusions: The C-SOSI is a reliable tool with converging validity for assessing stress symptoms in an oncology population. Further validation work is recommended to support use in other patient or community groups.